{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:19:51Z","timestamp":1794449991874,"version":"4.9.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2012,8,17]],"date-time":"2012-08-17T00:00:00Z","timestamp":1345161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1NR010162-01A1"],"award-info":[{"award-number":["RO1NR010162-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1CA1222292.01"],"award-info":[{"award-number":["RO1CA1222292.01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1CA124481-01"],"award-info":[{"award-number":["RO1CA124481-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["PEP-08-299-01-PC1"],"award-info":[{"award-number":["PEP-08-299-01-PC1"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction.<\/jats:title>\n                    <jats:p>Overweight women diagnosed with breast cancer have greater recurrence and mortality risks. Recent studies in advanced cancer showed that the combination of sarcopenia and an overweight or obese body mass index (BMI) is associated with poor clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives.<\/jats:title>\n                    <jats:p>To compare pathological complete response (pCR) cases with controls and evaluate associations among a pCR, survival outcome, and sarcopenia as well as the combination of both sarcopenia and a BMI \u226525 kg\/m2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>Sixty-seven breast cancer patients with a pCR to neoadjuvant chemotherapy (NC) were matched with controls who did not have a pCR to NC. Patients were matched by age, Black's nuclear grading system, clinical cancer stage, and estrogen receptor and progesterone receptor status. Body composition was analyzed using computed tomography images taken prior to NC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>BMI was associated with pCR. Among normal weight patients, the pCR rate was higher in sarcopenic patients and the progression-free survival (PFS) interval was significantly longer than in overweight or obese BMI patients. The death hazard was 2% higher for each unit higher skeletal muscle index and 0.6% higher for each unit higher visceral adipose tissue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>Overweight patients treated with NC had a lower pCR rate and shorter PFS time. Among patients with a normal BMI, the pCR rate was better in sarcopenic patients. More research is required to evaluate the negative impact of sarcopenic obesity on prognosis and the contributors to better response rates in operable, normal weight breast cancer patients with sarcopenia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2012-0169","type":"journal-article","created":{"date-parts":[[2012,8,18]],"date-time":"2012-08-18T00:53:07Z","timestamp":1345251187000},"page":"1240-1245","source":"Crossref","is-referenced-by-count":135,"title":["The Relationship Between Body Composition and Response to Neoadjuvant Chemotherapy in Women with Operable Breast Cancer"],"prefix":"10.1093","volume":"17","author":[{"given":"Egidio","family":"Del Fabbro","sequence":"first","affiliation":[{"name":"a Department of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique","family":"Parsons","sequence":"additional","affiliation":[{"name":"d Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla L.","family":"Warneke","sequence":"additional","affiliation":[{"name":"c Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyan","family":"Pulivarthi","sequence":"additional","affiliation":[{"name":"a Department of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Litton","sequence":"additional","affiliation":[{"name":"b Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rony","family":"Dev","sequence":"additional","affiliation":[{"name":"a Department of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shana L.","family":"Palla","sequence":"additional","affiliation":[{"name":"c Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abenaa","family":"Brewster","sequence":"additional","affiliation":[{"name":"b Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Bruera","sequence":"additional","affiliation":[{"name":"a Department of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,8,17]]},"reference":[{"key":"2021122308140077800_B1","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1158\/1055-9965.EPI-09-0372","article-title":"Obesity and cancer: The role of dysfunctional adipose tissue","volume":"18","author":"Kruijsdijk","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021122308140077800_B2","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2002.20.4.1128","article-title":"Weight loss in breast cancer patient management","volume":"20","author":"Chlebowski","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122308140077800_B3","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/oxfordjournals.aje.a009520","article-title":"Epidemiology of sarcopenia among the elderly in New Mexico","volume":"147","author":"Baumgartner","year":"1998","journal-title":"Am J Epidemiol"},{"key":"2021122308140077800_B4","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/gerona\/58.11.M1012","article-title":"Sarcopenia: Effects on body composition and function","volume":"58","author":"Roubenoff","year":"2003","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2021122308140077800_B5","doi-asserted-by":"crossref","first-page":"e29330","DOI":"10.1371\/journal.pone.0029330","article-title":"Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service","volume":"7","author":"Parsons","year":"2012","journal-title":"PLoS One"},{"key":"2021122308140077800_B6","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","article-title":"Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment","volume":"15","author":"Prado","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122308140077800_B7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00280-010-1288-y","article-title":"An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity","volume":"67","author":"Prado","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122308140077800_B8","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/annonc\/mdp605","article-title":"Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma","volume":"21","author":"Antoun","year":"2010","journal-title":"Ann Oncol"},{"key":"2021122308140077800_B9","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1200\/JCO.2007.14.4527","article-title":"Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer","volume":"26","author":"Litton","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308140077800_B10","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1200\/JCO.2005.02.6914","article-title":"Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors","volume":"24","author":"Guarneri","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308140077800_B11","doi-asserted-by":"crossref","first-page":"9304","DOI":"10.1200\/JCO.2005.02.5023","article-title":"Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy","volume":"23","author":"Hennessy","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308140077800_B12","volume-title":"National Institutes of Health\/National Heart, Lung, and Blood Institute: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults"},{"key":"2021122308140077800_B13","first-page":"53","article-title":"Adipose tissue volume determinations in women by computed tomography: Technical considerations","volume":"10","author":"Kvist","year":"1986","journal-title":"Int J Obes"},{"key":"2021122308140077800_B14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"key":"2021122308140077800_B15","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.1158\/1078-0432.CCR-09-1525","article-title":"Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer","volume":"15","author":"Tan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122308140077800_B16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2165\/00003088-199426040-00005","article-title":"Lean body mass as a predictor of drug dosage. Implications for drug therapy","volume":"26","author":"Morgan","year":"1994","journal-title":"Clin Pharmacokinet"},{"key":"2021122308140077800_B17","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1210\/jc.2004-1306","article-title":"Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases","volume":"90","author":"Santini","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122308140077800_B18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","article-title":"Prognostic effect of weight loss prior to chemotherapy in cancer patients","volume":"69","author":"Dewys","year":"1980","journal-title":"Am J Med"},{"key":"2021122308140077800_B19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: An international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021122308140077800_B20","doi-asserted-by":"crossref","first-page":"1133S","DOI":"10.3945\/ajcn.2010.28608C","article-title":"Body composition in patients with non-small cell lung cancer: A contemporary view of cancer cachexia with the use of computed tomography image analysis","volume":"91","author":"Baracos","year":"2010","journal-title":"Am J Clin Nutr"},{"key":"2021122308140077800_B21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.clnu.2011.12.008","article-title":"Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function","volume":"31","author":"Stephens","year":"2012","journal-title":"Clin Nutr"},{"key":"2021122308140077800_B22","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/(SICI)1097-0142(19961115)78:10<2119::AID-CNCR12>3.0.CO;2-1","article-title":"Gender influence on weight-loss pattern and survival of nonsmall cell lung carcinoma patients","volume":"78","author":"Palomares","year":"1996","journal-title":"Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2012-0169","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2012-0169","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/10\/1240\/41858569\/oncolo_17_10_1240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/10\/1240\/41858569\/oncolo_17_10_1240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T15:28:29Z","timestamp":1640273309000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/10\/1240\/6400882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,17]]},"references-count":22,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2012,8,17]]},"published-print":{"date-parts":[[2012,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2012-0169","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,10,1]]},"published":{"date-parts":[[2012,8,17]]}}}